| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
EC90: <0.35 μM (influenza virus A and B)[1]
2'-Deoxy-2'-fluoroguanosine is an influenza viral polymerase inhibitor. As a nucleoside analog, it mimics guanosine structure and is incorporated into viral RNA during replication, leading to chain termination or mutagenesis. The compound inhibits influenza A and B viruses with EC90 values <0.35 μM. The mechanism of action involves its incorporation into oligonucleotides, which then exhibit high affinity and specificity for RNA targets. The 2'-fluoro modification enhances metabolic stability and binding affinity to the viral polymerase. |
|---|---|
| ln Vitro |
2'-Deoxy-2'-fluoroguanosine demonstrates potent in vitro antiviral activity against influenza A and B viruses with EC90 values <0.35 μM. It is an influenza viral polymerase inhibitor like Ribavirin. The compound inhibits viral replication through incorporation into viral RNA, leading to chain termination or mutagenesis. The 2'-fluoro modification enhances the compound's stability and binding affinity to the viral polymerase. Detailed IC50 values and spectrum of activity are available in the antiviral research literature.
|
| ln Vivo |
2'-Deoxy-2'-fluoroguanosine significantly inhibits replication of influenza virus in the upper respiratory tract, resulting in amelioration of fever and nasal inflammation in animal models. The compound demonstrates in vivo efficacy against avian (H5N1) influenza virus. As a nucleoside analog, it is incorporated into viral RNA and inhibits viral replication. The compound's efficacy in the upper respiratory tract makes it a promising candidate for the treatment of influenza infections.
|
| Enzyme Assay |
For influenza virus polymerase inhibition assays, purified influenza virus polymerase is incubated with viral RNA template, nucleotides (including radiolabeled or fluorescently labeled nucleotides), and 2'-Deoxy-2'-fluoroguanosine at various concentrations. Polymerase activity is measured by incorporation of labeled nucleotides into RNA products, which are analyzed by gel electrophoresis or scintillation counting. IC50 or EC90 values are calculated from dose-response curves. For antiviral assays, virus-infected cells are treated with the compound and viral replication is assessed by plaque reduction or qRT-PCR.
|
| Cell Assay |
For antiviral activity evaluation, MDCK or other susceptible cells are cultured in appropriate media and infected with influenza virus at a suitable multiplicity of infection. Cells are treated with 2'-Deoxy-2'-fluoroguanosine at various concentrations (typically 0.001-100 μM) for 24-48 hours post-infection. Viral replication is assessed by plaque reduction assays, where infected cells are overlayed with agarose containing the compound and plaques are counted after staining. Alternatively, viral RNA is quantified by qRT-PCR, or viral protein expression is assessed by immunofluorescence. Cytotoxicity is assessed in parallel using MTT assays.
|
| Animal Protocol |
For in vivo efficacy studies, mice are infected with influenza virus (e.g., H5N1) intranasally. 2'-Deoxy-2'-fluoroguanosine is administered by appropriate routes (oral, intraperitoneal, or intranasal) at various doses. Survival is monitored, and body weight is measured daily. At study termination, viral titers in lung and upper respiratory tract tissues are determined by plaque assay or qRT-PCR. Fever and nasal inflammation are assessed as clinical endpoints. Pharmacokinetic studies are conducted to determine compound exposure in plasma and respiratory tissues.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2'-Deoxy-2'-fluoroguanosine have been characterized in preclinical studies. The compound has a molecular weight of 285.23 and is a nucleoside analog with moderate water solubility. As a nucleoside analog, it is expected to be phosphorylated intracellularly to the active triphosphate form. The 2'-fluoro modification enhances metabolic stability by reducing susceptibility to nucleoside phosphorylases. Detailed PK parameters including bioavailability, half-life, and tissue distribution are available in the primary literature.
|
| Toxicity/Toxicokinetics |
2'-Deoxy-2'-fluoroguanosine is a research compound intended for laboratory use only and is not approved for human therapeutic use. As an influenza viral polymerase inhibitor, it has demonstrated activity against avian (H5N1) influenza virus. The compound significantly inhibits replication of influenza virus in the upper respiratory tract. Standard laboratory safety precautions should be followed when handling this compound. Toxicological studies have been conducted as part of preclinical development.
|
| References | |
| Additional Infomation |
2'-Deoxy-2'-fluoroguanosine is a synthetic purine nucleoside analog with molecular formula C10H12FN5O4 and molecular weight 285.23. It is an influenza viral polymerase inhibitor with EC90 values <0.35 μM against influenza A and B viruses. The compound significantly inhibits influenza virus replication in the upper respiratory tract, improving fever and nasal inflammation. It is active against avian (H5N1) influenza virus. The compound is for research use only and has not been approved for clinical applications.
|
| Molecular Formula |
C10H12FN5O4
|
|---|---|
| Molecular Weight |
285.23
|
| Exact Mass |
285.087
|
| CAS # |
78842-13-4
|
| PubChem CID |
135415565
|
| Appearance |
White to off-white solid powder
|
| Density |
2.2±0.1 g/cm3
|
| Index of Refraction |
1.876
|
| LogP |
-0.53
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
449
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)F)N=C(NC2=O)N
|
| InChi Key |
UXUZARPLRQRNNX-DXTOWSMRSA-N
|
| InChi Code |
InChI=1S/C10H12FN5O4/c11-4-6(18)3(1-17)20-9(4)16-2-13-5-7(16)14-10(12)15-8(5)19/h2-4,6,9,17-18H,1H2,(H3,12,14,15,19)/t3-,4-,6-,9-/m1/s1
|
| Chemical Name |
2-amino-9-[(2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 50 mg/mL (175.30 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.76 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.76 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.76 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5059 mL | 17.5297 mL | 35.0594 mL | |
| 5 mM | 0.7012 mL | 3.5059 mL | 7.0119 mL | |
| 10 mM | 0.3506 mL | 1.7530 mL | 3.5059 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
